All In Biotech

Drug Trial Radar · NCT06358651

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-3)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

238

Actual

Start

Mar 28, 2024

Primary completion

Oct 31, 2025

Study completion Jul 13, 2026

Sponsor

Lead sponsor
VistaGen Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-3 and choose to enter the distinct open-label extension phase of the study.

Conditions

  • Social Anxiety Disorder

Interventions

  • Fasedienol Nasal SprayDrug

    Nasal spray delivered 20 minutes before the PSC

  • Placebo Nasal SprayDrug

    Nasal spray delivered 20 minutes before the PSC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjective Units of Distress Scale (SUDS)Time frame: 7 days (Visit 2 to Visit 3)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Vistagen Clinical Site

    Phoenix, Arizona

  • Vistagen Clinical Site

    Fayetteville, Arkansas

  • Vistagen Clinical Site

    Little Rock, Arkansas

  • Vistagen Clinical Site

    Lafayette, California

  • Vistagen Clinical Site

    Oceanside, California

  • Vistagen Clinical Site

    Sherman Oaks, California

  • Vistagen Clinical Site

    Denver, Colorado

  • Vistagen Clinical Site

    Cromwell, Connecticut

  • Vistagen Clinical Site

    Jacksonville, Florida

  • Vistagen Clinical Site

    Lakeland, Florida

  • Vistagen Clinical Site

    Orlando, Florida

  • Vistagen Clinical Site

    West Palm Beach, Florida

  • Vistagen Clinical Site

    Chicago, Illinois

  • Vistagen Clinical Site

    Overland Park, Kansas

  • Vistagen Clinical Site

    Baltimore, Maryland

  • Vistagen Clinical Site

    Boston, Massachusetts

  • Vistagen Clinical Site

    Saint Charles, Missouri

  • Vistagen Clinical Site

    Las Vegas, Nevada

  • Vistagen Clinical Site

    New York, New York

  • Vistagen Clinical Site

    Media, Pennsylvania

  • Vistagen Clinical Site

    Memphis, Tennessee

  • Vistagen Clinical Site

    Fort Worth, Texas

  • Vistagen Clinical Site

    Draper, Utah

  • Vistagen Clinical Site

    Everett, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.